CD47 and cancer: From a translational perspective, the link between KRAS mutations and innate immune evasion suggests that targeting the KRAS/CD47 axis might compromise the ability of cancer cells to evade innate immune surveillance and increase their susceptibility to macrophage phagocytosis.